
Drug companies are quietly pushing through price hikes of 100 percent, or even more than 1,000 percent, for a small but growing number of prescription drugs.
The number of brand-name drugs with increases of 100 percent or more could double compared to four years ago, according to researchers. Many of the drugs treat fairly rare, but often serious or even life-threatening, conditions.
Questcor Pharmaceuticals raised the wholesale price on Acthar, which treats spasms in babies, from about $1,650 a vial to more than $23,000. Ovation raised the cost of Cosmegen, which treats a type of tumor, from $16.79 to $593.75.
The average wholesale price of 26 brand-name drugs jumped 100 percent or more in a single cost adjustment, up from 15 in 2004.